Concise review

Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products

Yunjoon Jung, Gerhard Bauer, Jan Nolta

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with "safe harbor" vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalStem Cells
Volume30
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Induced Pluripotent Stem Cells
Mesenchymal Stromal Cells
Cell- and Tissue-Based Therapy
Hematopoietic System
Adult Stem Cells
Genetic Engineering
Embryonic Stem Cells
Fetal Blood
Transgenes
Clone Cells
Transplantation
Bone Marrow
Clinical Trials
Wounds and Injuries
Therapeutics

Keywords

  • Cellular therapy
  • Clinical trials
  • Induced pluripotent stem cells
  • Mesenchymal stem cells
  • Regenerative medicine

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology
  • Molecular Medicine

Cite this

Concise review : Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products. / Jung, Yunjoon; Bauer, Gerhard; Nolta, Jan.

In: Stem Cells, Vol. 30, No. 1, 01.2012, p. 42-47.

Research output: Contribution to journalArticle

@article{b67e3ab6be4c48a3b6636d1171cf3667,
title = "Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products",
abstract = "Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with {"}safe harbor{"} vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.",
keywords = "Cellular therapy, Clinical trials, Induced pluripotent stem cells, Mesenchymal stem cells, Regenerative medicine",
author = "Yunjoon Jung and Gerhard Bauer and Jan Nolta",
year = "2012",
month = "1",
doi = "10.1002/stem.727",
language = "English (US)",
volume = "30",
pages = "42--47",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Concise review

T2 - Induced pluripotent stem cell-derived mesenchymal stem cells: Progress toward safe clinical products

AU - Jung, Yunjoon

AU - Bauer, Gerhard

AU - Nolta, Jan

PY - 2012/1

Y1 - 2012/1

N2 - Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with "safe harbor" vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.

AB - Adult stem cell therapies have provided success for more than 50 years, through reconstitution of the hematopoietic system using bone marrow, umbilical cord blood, and mobilized peripheral blood transplantation. Mesenchymal stem cell (MSC)-mediated therapy is a fast-growing field that has proven safe and effective in the treatment of various degenerative diseases and tissue injuries. Since the first derivation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), there has been impressive progress toward developing safe clinical applications from PSCs. Recent successes in transgene-free iPSC reprogramming have brought attention to the potential of clinical applications of these pluripotent cells, but key hurdles must be overcome, which are discussed in this review. Looking to the future, it could be advantageous to derive MSC from iPSC or human ESC in cases where genetic engineering is needed, since in the PSCs, clones with "safe harbor" vector integration could be selected, expanded, and differentiated. Here, we describe the status of the progress of the use of MSC and PSCs in clinical trials and analyze the challenges that should be overcome before iPSC-derived MSC therapy can be used widely in the clinic.

KW - Cellular therapy

KW - Clinical trials

KW - Induced pluripotent stem cells

KW - Mesenchymal stem cells

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=84855407207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855407207&partnerID=8YFLogxK

U2 - 10.1002/stem.727

DO - 10.1002/stem.727

M3 - Article

VL - 30

SP - 42

EP - 47

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 1

ER -